Prognostic and clinicopathological significance of the platelet‐to‐lymphocyte ratio in melanoma: A meta‐analysis involving 2099 patients

Han, Sai-Nan; Feng, Shijun; Liu, Yuan

doi:10.1002/kjm2.12290

Cited by 5 publications

(4 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A meta-analysis ( [109], Table 3) conducted by Sai-Nan Han et al, investigating the prognostic role of the platelet-to-lymphocyte ratio (PLR) in melanoma, showed no significant association between PLR and sex (OR = 1.14, 95% CI 0.23-5.66; p = 0.87). There was no publication bias, although there may be selection biases and unacknowledged confounding factors typical of retrospective cohort studies.…”

Section: Sex/gender As a Potential Prognostic Factor For Melanomamentioning

confidence: 99%

Gender-Dependent Specificities in Cutaneous Melanoma Predisposition, Risk Factors, Somatic Mutations, Prognostic and Predictive Factors: A Systematic Review

D’Ecclesiis

Caini²,

Martinoli

et al. 2021

IJERPH

View full text Add to dashboard Cite

Background and aim: Over the last decades, the incidence of melanoma has been steadily growing, with 4.2% of the population worldwide affected by cutaneous melanoma (CM) in 2020 and with a higher incidence and mortality in men than in women. We investigated both the risk factors for CM development and the prognostic and predictive factors for survival, stratifying for both sex and gender. Methods: We conducted a systematic review of studies indexed in PUB-MED, EMBASE, and Scopus until 4 February 2021. We included reviews, meta-analyses, and pooled analyses investigating differences between women and men in CM risk factors and in prognostic and predictive factors for CM survival. Data synthesis: Twenty-four studies were included, and relevant data extracted. Of these, 13 studies concerned potential risk factors, six concerned predictive factors, and five addressed prognostic factors of melanoma. Discussion: The systematic review revealed no significant differences in genetic predisposition to CM between males and females, while there appear to be several gender disparities regarding CM risk factors, partly attributable to different lifestyles and behavioral habits between men and women. There is currently no clear evidence of whether the mutational landscapes of CM differ by sex/gender. Prognosis is justified by a complex combination of phenotypes and immune functions, while reported differences between genders in predicting the effectiveness of new treatments are inconsistent. Overall, the results emerging from the literature reveal the importance of considering the sex/gender variable in all studies and pave the way for including it towards precision medicine. Conclusion: Men and women differ genetically, biologically, and by social construct. Our systematic review shows that, although fundamental, the variable sex/gender is not among the ones collected and analyzed.

show abstract

Section: Sex/gender As a Potential Prognostic Factor For Melanomamentioning

confidence: 99%

Gender-Dependent Specificities in Cutaneous Melanoma Predisposition, Risk Factors, Somatic Mutations, Prognostic and Predictive Factors: A Systematic Review

D’Ecclesiis

Caini²,

Martinoli

et al. 2021

IJERPH

View full text Add to dashboard Cite

show abstract

“…Similar to our findings, a recent meta-analysis investigating the prognostic value of the PLR in patients with melanoma found that an elevated PLR was associated with poor OS but not PFS ( 36 ). However, another meta-analysis failed to show any obvious association between PRL and OS or PFS in patients with melanoma ( 37 ). Small sample sizes in these studies were a significant limitation, and further prospective studies are needed to clarify contradictory results.…”

Section: Discussionmentioning

confidence: 99%

Prognostic Value of the Neutrophil-to-lymphocyte Ratio, Platelet-to- lymphocyte Ratio and Monocyte-to-lymphocyte Ratio in Melanoma Patients: A Cohort Study

Ertekin,

Mangas,

Riquelme-Mc Loughlin

et al. 2024

Acta Derm Venereol

View full text Add to dashboard Cite

The prognostic value of the neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and monocyte-lymphocyte ratio in patients with melanoma has yielded controversial results in the literature. A retrospective single-centre cohort study was conducted from 1998 to 2020, including patients diagnosed with invasive melanoma. A total of 2,721 patients were included in the study. The median follow-up was 8.23 years (IQR 4.41–13.25). The median baseline neutrophil- lymphocyte ratio, platelet-lymphocyte ratio and monocyte-lymphocyte ratio values increased significantly (p < 0.001) with the increasing American Joint Committee on Cancer stage. The optimal cut-off values for neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and monocyte-lymphocyte ratio were determined as 2.1, 184 and 0.2, respectively. In the multivariate analysis, high levels of neutrophil-lymphocyte ratio (≥ 2.1), platelet-lymphocyte ratio (≥ 184) and monocyte-lymphocyte ratio (≥ 0.2) were independently associated with significantly shorter melanoma-specific survival (neutrophil-lymphocyte ratio: HR 1.30, 95% CI 1.06–1.60, p = 0.013; platelet-lymphocyte ratio: HR 1.37, 95% CI 1.06–1.76, p = 0.014; monocyte- lymphocyte ratio: HR 1.29, 95% CI 1.05–1.58, p = 0.015) and overall survival (neutrophil-lymphocyte ratio: HR 1.39, 95% CI 1.19–1.64, p < 0.001; platelet- lymphocyte ratio: HR 1.44, 95% CI 1.19–1.74, p < 0.001; monocyte-lymphocyte ratio: HR 1.42, 95% CI 1.21–1.66, p < 0.001). High levels of neutrophil- lymphocyte ratio and monocyte-lymphocyte ratio were also associated with poor relapse-free survival, while platelet-lymphocyte ratio was not. In conclusion, baseline neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and monocyte-lymphocyte ratio were identified as independent predictors for the prognosis of melanoma.

show abstract

“…Platelets are also well-known as an important indicator of systemic inflammation [15] by secreting various cytokines to support tumor growth, protecting tumors from apoptosis, and promoting tumor metastasis [16]. The prognostic and predictive roles of platelets and the Platelet to Lymphocyte Ratio (PLR) in melanomas have been less investigated, and published data remain controversial [17,18].…”

Section: Introductionmentioning

confidence: 99%

Use of Platelet to Lymphocyte Ratio for Prediction of ProgressionFree Survival in Patients with Advanced Melanoma Treated with First-Line Immune Checkpoint Inhibitors

Kim

2023

J Oncology

View full text Add to dashboard Cite

show abstract

Prognostic and clinicopathological significance of the platelet‐to‐lymphocyte ratio in melanoma: A meta‐analysis involving 2099 patients

Cited by 5 publications

References 32 publications

Gender-Dependent Specificities in Cutaneous Melanoma Predisposition, Risk Factors, Somatic Mutations, Prognostic and Predictive Factors: A Systematic Review

Gender-Dependent Specificities in Cutaneous Melanoma Predisposition, Risk Factors, Somatic Mutations, Prognostic and Predictive Factors: A Systematic Review

Prognostic Value of the Neutrophil-to-lymphocyte Ratio, Platelet-to- lymphocyte Ratio and Monocyte-to-lymphocyte Ratio in Melanoma Patients: A Cohort Study

Use of Platelet to Lymphocyte Ratio for Prediction of ProgressionFree Survival in Patients with Advanced Melanoma Treated with First-Line Immune Checkpoint Inhibitors

Contact Info

Product

Resources

About